Vaccine

COVID-19 Vaccine

Frequently Asked Questions

The rollout of COVD-19 vaccines has started in several countries. In Australia, the vaccine will be administered in a series of phases in 2021 in an effort to prevent the spread of COVID-19 and protect Australians against the virus. The vaccines will become available at hospitals, health clinics, GPs clinics and approved pharmacies. As the government roll-out continues, Lung Foundation Australia will monitor reputable sources for information to help answer your questions.

The following information is based on the Australian Government’s COVID-19 vaccines information, available at health.gov.au.

Live Well, Breathe Better Webinar: COVID-19 Vaccination Information

When: Monday, 10 May

Time: 6.30pm (ACT, NSW, QLD, TAS, VIC) 6.00pm (NT, SA) 4.30pm (WA)

You may have questions about how the vaccines work, their effectiveness and what possible side effects they may have. In this webinar our expert speaker will summarise how the vaccines work and answer your frequently asked questions. A live question-and-answer session will also be available during the webinar for you to submit questions.

About the COVID-19 vaccine

  • How does the COVID-19 vaccine work?

    Like many vaccines, the COVID-19 vaccine trains your immune system to recognise a virus, in this case the one that causes COVID-19, as dangerous and fight it. This vaccine will work in the same way that other vaccines you may already receive dosuch as influenza and pneumococcal pneumonia. Some vaccines contain either inactive or weakened versions of the virus that causes the infection, while others teach our bodies how to make a protein that triggers an immune response in our bodies. However, they are all designed to allow your body to develop a supply of defensive white blood cells that will remember how to fight the virus. This process can take a few weeks so it is still possible to become unwell if you are infected by the virus that causes COVID-19 just before or just after receiving the vaccine.

     

  • What is the difference between the vaccinations currently being administered to Australians?

    Both the Pfizer and AstraZeneca vaccines use the body’s own cells to produce a protein that is unique to the virus. Once this protein has developed, the body’s immune system automatically produces the cells needed to destroy it. It learns and remembers this defensive process and will activate that process if it comes across the protein again. However the two vaccines use different technologies to stimulate the immune response in the body.

    The Pfizer vaccine, which needs to be stored at very low temperatures (-70C or below), is known as an mRNA vaccine. While some vaccines use a weakened or inactive germ to trigger an immune response, mRNA vaccines teach our cells to make protein, in this case a harmless piece of the spike protein found on the surface of the virus that causes COVID-19. When our immune system detects the protein, which doesn’t belong, it starts making antibodies and commits this process to memory.

    The AstraZenca vaccine, which can be stored at normal refrigeration temperatures, is known as a viral vector vaccine. This type of vaccine uses a modified version of another virus, in this case a common cold virus, which has been altered to look like coronavirus. As with an mRNA vaccine, the body’s immune system kicks in, starts making antibodies and primes to attack the virus.

    There are also differences in the time and dosing required. The Pfizer vaccine requires two doses, 21 days apart while AstraZeneca’s needs two doses given 4-12 weeks apart. The first dose helps your body recognise the virus and starts the immune response, and the second dose helps to strengthen that immune response to better prepare your body to fight the real virus if needed.

  • Have the vaccines been through the required approval process?

    Yes, they have. Given the urgency, this approval has been fast-tracked but no corners have been cutAustralia’s Therapeutic Goods Administration (TGA) has a rigorous process covering safety, quality and effectiveness. Before any vaccine is approved, it is tested extensively through laboratory research, animal studies and human clinical trials. It is also worth noting that researchers started work on COVID-19 vaccinations early last year, soon after cases first started emerging worldwide. Both the Pfizer and AstraZeneca vaccines have been approved by the TGA. 

  • What does that latest government advice on the AstraZeneca vaccine mean for me?

    The Australian Technical Advisory Group on Immunisation (ATAGI) has issued a statement recommending that the COVID-19 Pfizer vaccine is preferred over the AstraZeneca vaccine for adults under 50. This is in response to a rare but serious side effect involving blood clotting.

    The ATAGI still recommends all adults be vaccinated against COVID-19 as an essential step to protect the community. If you’re currently eligible to receive the COVID-19 vaccine, we encourage you talk to your GP about your individual circumstances and health history.

  • When will they be available in Australia and what are the priority groups?

    The first group of Australians started to receive vaccinations on February 22. The Government’s priority is to protect the most vulnerable” first, which includes health and aged care workers (phase 1A)followed by those aged over 70 and adults with an underlying medical condition, including a chronic lung disease (phase 1B, from March 22). The Government will continue to release details regarding priority groups and vaccination timings through an ongoing public information campaign. 
     
    Everyone who wants a vaccine should have been offered one by the end of October this year.

     

  • I qualify for the phase 1B rollout, how do I book my vaccination?

    While the rollout of phase 1B officially starts on 22 March 2021, it may take some time for vaccine supply levels to increase across the country. GP clinics are already experiencing high volumes of enquiries and are encouraging people to be patient. As more locally produced AstraZeneca vaccines become available, appointment availability will increase. 

    The Government Eligibility Checker allows you to find locations near you that will be administering the vaccine and provides advice on how to book at each location. Many GP practices are asking people to utilise their online booking system, where available. 

    Phase 1B includes those aged over 70adults with medical conditions including chronic lung disease (but not mild to moderate asthma), and aged care and healthcare workers – nearly 680,000 peopleMore than 1,000 GP clinics, which should increase to 4,000 by April, plus Aboriginal Commonwealth Controlled Health Services, will administer the vaccine to these vulnerable groups. Details of underlying medical conditions covered are available here or you can ring the National Coronavirus Hotline on 1800 020 080.  

  • What is the latest on the rollout of the vaccine to over-50s?

    The National Cabinet has agreed to expand the rollout of the AstraZeneca vaccine to over-50s through state-run hubs from May 3, and from GPs from May 17. People in phase 2A (over 50) are encouraged to find a vaccine facility through the government’s eligibility checker. If you are eligible to book, local clinics in your area will be identified through the checker. It may take time for vaccine supply levels to increase so be patient; appointment availability will increase as it does. 

  • Are there other vaccinations being trialled?

    There are many vaccines being developed and trialled around the world. Novavax is another being developed in Australia while there are many more being developed globally. 

  • Where will the vaccines be administered?

    Vaccines will be administered at state-run hubs, hospitals, general practices, health clinics, Aboriginal Community Controlled Health Organisations and pharmacies which have expressed interest and been approved. All COVID-19 vaccinations administered will be recorded on to the Australian Immunisation Register. 

  • How effective are the approved vaccines in preventing severe illness or hospitalisation?

    Health authorities say the vaccines approved in Australia are both extremely effective in preventing severe cases. The Pfizer vaccine has a reported efficacy of 95 per cent while research has found that the AstraZeneca vaccine has an 81 per cent efficacy rate after the second dose. The World Health Organisation has backed the use of the AstraZeneca vaccine for all ages. Efficacy rates mean that, for example, the vaccine prevents COVID-19 disease in 95 per cent of people who receive it.   

  • Will older people with diseases be prioritised above older people without diseases?

    The Government has stated that all people aged over 70 will be included in Phase 1 of the vaccine roll-out. The Department of Health has listed those with chronic lung disease and chronic inflammatory conditions as among those at “high or moderate risk” and therefore in the initial phase (1B) of vaccination eligibility. 

  • How will I know when it is my turn to receive the vaccine?

    For the initial Phase 1A group, either the Government or your employer will let you know via official channels. For later groups, updated information will be released by the Government. You can check where you are in the queue courtesy of the Government’s eligibility checker (click here).

  • Why do we need to have two doses spaced apart?

    The first dose primes the pump (getthe antibodies going), the second trains the T cells which hold the memory of the virus for future infections.ii 

  • Will there be enough vaccines available for everyone?

    The Government has purchased 2million doses of the Pfizer vaccine, having announced an additional 10m doses on February 4, 2021, and has 53.8m doses of the AstraZeneca vaccine (manufactured here in Australia) on order, along with 51m Novavax doses. 

  • How soon will the vaccine have an impact on COVID-19 numbers?

    It is too early to know when these current vaccines will enable Australia, or countries worldwide, to achieve “herd immunity” (enough people in community protected from contracting COVID-19); or when/if they will enable a “return to normal”. The key at this stage is to reduce the number of people infected and prevent severe cases requiring hospitalisation. Safe and effective vaccines can reduce the health, social and economic impact of the pandemic and save lives. Social distancing and good hygiene habits will, however, remain essential.

Vaccines and lung conditions